newsfilter
← Latest News
PR Newswire·

Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs

CYRX
  • Cryoport's IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support process development, technology transfer, and clinical cryopreservation for SynKIR™-110 & SynKIR™-310.
  • Verismo's SynKIR™-110 is currently in the STAR-101 Phase 1 trial for advanced mesothelin-expressing solid tumors.
  • Verismo's SynKIR™-310 is currently in the CELESTIAL-301 Phase 1 trial for relapsed or refractory B-cell non-Hodgkin lymphomas.
  • Both candidates are in human clinical trials with initial Phase 1 data presented at the AACR 2026 Annual Meeting.
  • IntegriCell provides standardized, GMP-compliant cryopreservation to reduce variability, improve manufacturing efficiency, and derisk supply chains for Verismo's programs.
  • Cryoport implemented Verismo's proprietary cryopreservation process within its global quality management system to ensure consistency & reliability.
  • IntegriCell service centers are located in Houston, Texas, & Liège, Belgium, to support clinical & commercial programs across the Americas & Europe.
  • The partnership integrates with Cryoport's broader supply chain platform including biologistics, biostorage, informatics, & Cryoshuttle® transport services.
  • Cryoport Systems supports high-quality allogeneic starting materials through a strategic alliance with Gulf Coast Regional Blood Center for donor recruitment & apheresis.
  • Verismo Therapeutics is the only company developing the multi-chain KIR-CAR platform which uses a modified NK cell-derived receptor & DAP12 pairing to reduce T cell exhaustion.